Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

able, less current portion - 119,000

Capital lease obligation, less current portion 17,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock-$.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock-$.001 par value; authorized

325,000,000 shares; outstanding -

226,210,617 and 196,112,201, respectively 226,000 196,000

Additional paid-in capital 245,982,000 224,453,000

Accumulated deficit (224,677,000) (207,660,000)

Total stockholders' equity 21,531,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $28,241,000 $22,997,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED NINE MONTHS ENDED

January 31, January 31, January 31 January 31,

2008 2007 2008 2007

Unaudited Unaudited Unaudited Unaudited

REVENUES:

Contract

manufacturing

revenue $1,662,000 $347,000 $5,146,000 $1,381,000

License revenue 13,000 16,000 46,000 87,000

Total revenues 1,675,000 363,000 5,192,000 1,468,000

COSTS AND EXPENSES:

Cost of contract

manufacturing 1,289,000 223,000 3,872,000 1,247,000

Research and

development 4,941,000 3,907,000 13,665,000 11,868,000

Selling, general

and administrative 1,847,000 1,513,000 5,498,000 4,824,000

Total costs

and expenses
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 01, 2015 , ... A new host-based therapy for Ebola, ... Keck Graduate Institute and its collaborators. The discovery has the potential to speed ... on August 27 by Scientific Reports, an open access research journal from the ...
(Date:8/31/2015)... , Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $5.7 million. The orders are for air emission abatement projects in ... note is a large order for a municipality in the ... be replacing a competitor,s system that failed to meet the ... engineered solutions," said Derek S. Webb , President and ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... market is estimated at $0.19 billion by 2018 at ... The near future will bring biomedical sensors that ... These sensors can be set to trigger alerts when ...
(Date:8/31/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... scientific review has identified high value opportunities for ... patient need. Novogen is moving as quickly as ... entering into Phase 1 clinical trials with our ... Officer, Iain Ross , said that following ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today ... an additional 180 days to regain compliance with NASDAQ,s $1.00 ... on May 3, 2010, CTI was notified by NASDAQ that ... for continued listing and was provided until November 1, 2010 ...
... Nov. 2, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has granted marketing approval for ... formulation of acetaminophen to be approved in the United ... to moderate pain, the management of moderate to severe ...
... 2, 2010 Modern Plastics offers SUSTARIN® C ... manufactured by ROCHLING Engineering Plastics. The technology ... sheet and rod are free of centerline or core ... stability for close tolerance parts. A low coefficient of ...
Cached Biology Technology:NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule 2Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 2Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 3Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 4Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 5Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 6Modern Plastics SUSTARIN® C (Acetal) Product Uses Special Manufacturing Technology to Ensure Every Sheet and Rod Are Free of Centerline or Core Porosity 2
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... the short end of the stick, in this case the ... at the ends of chromosomes, can be thought of as ... neighboring chromosomes. It is typical for telomeres to ... a new study from Brigham and Women,s Hospital (BWH) suggest ...
... to the way scientists name new plants that took effect ... Latin requirement - a stipulation that descriptions or diagnoses of ... rules make it possible to take full advantage of an ... particular species is indeed new to science: Many studies now ...
... 2012Healthy individuals who carry a gene variation linked to ... their brains that may help explain how the gene ... results of this innovative brain imaging study are described ... Brain Connectivity, a bimonthly peer-reviewed publication from Mary ...
Cached Biology News:The long, err, short of it 2
Human Glypican 2 Biotinylated Affinity Purified PAb...
B2-Microgloulin...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
...
Biology Products: